Canada confirms need for reforms in devices testing framework
This article was originally published in RAJ Devices
There is agreement within the Canadian medtech industry that Health Canada needs to initiate reforms to better manage risks associated with the investigational testing (ie clinical investigation) of medical devices1.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.